Benzinga
Benzinga
Benzinga
sabato, settembre 26

Palisade Bio Inc

PALINASDAQ
Trade with Public
Trade with Public
$1.45
-0.12-7.64%
In chiusura: Sep 25, 5:00 PM EST
$1.49
0.03882.68%
Post-mercato: 7:59 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaRapporto azionario

Palisade Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Palisade Bio (PALI).

Price Target Range — 8 Quarters

Analyst Consensus — 9 Analysts

9Buy
Consensus RatingBuy# Analysts9Avg. Consensus PT$11Upside to Avg. PT+609.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Sep 23, 2026HC Wainwright & Co.Mitchell S. KapoorMaintainedBuy$7
Jul 23, 2026OppenheimerLeland GershellInitiateOutperform$8
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $7 price target.
Benzinga Newsdesk

Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2

Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.
Vandana Singh

This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top analysts change outlook on top names. See all changes and ratings on our analyst ratings page. Check out what analysts think about SIG stock.
Avi Kapoor

PRO
Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8

Oppenheimer analyst Leland Gershell initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $8.
Benzinga Newsdesk

PRO
Wolfe Research Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $7

Wolfe Research analyst Andy Chen initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $7.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $7

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $7.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved